Opdivo (Nivolumab) for the Treatment of Unresectable or Metastatic Melanoma
Opdivo (nivolumab) is indicated for the treatment of unresectable or metastatic melanoma in...
Trending menu:
-
![]()
Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes
-
![Digital Research]()
Scientist.com and Austrade to expand digital research marketplace in Australia
-
![]()
Elligo Health unveils new clinical trials technology
-
![]()
Olumiant (baricitinib) for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
-
![]()
Cabometyx (cabozantinib) for Treatment of Patients with Advanced Renal Cell Carcinoma
-
![]()
Keytruda (pembrolizumab) for the Treatment of Metastatic Melanoma
Most Read
- Celltrion implements Veeva Vault eTMF to improve visibility into clinical trial activities
- Parexel launches integrated FPS model to drive delivery of clinical research partnerships
- Medable unveils telemedicine solution only for clinical trials
- Broader inclusion criteria to double eligible cancer patients for clinical trials, finds study
- Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
Company A-Z
Latest Content
Signant Health to assist Shanghai Mental Health Center in trial
Shanghai Mental Health Center (SMHC) has selected Signant Health to provide electronic informed consent for a neuroscience study on schizophrenia.
August’s top news stories
Biopharmaceutical firm Retrophin reported that the Phase III clinical trial of fosmetpantotenate failed to meet endpoints in pantothenate kinase-associated neurodegeneration (PKAN) patients; and MyoKardia has commenced dosing of patients in a Phase I trial of small molecule MYK-224 for the treatment of hypertrophic cardiomyopathy (HCM). Clinicaltrialsarena.com wraps up the key headlines from August 2019.
IQVIA enables direct patient access to trial information
IQVIA has launched a new web-based solution to offer patients a direct access point for clinical trial information following their enrolment.
C-Path, NORD launch FDA-funded rare disease data and analytics platform
Independent non-profit organisation Critical Path Institute (C-Path) and advocacy organisation National Organisation for Rare Disorders (NORD) are set to formally launch development of a new rare disease data and analytics platform.
Symphogen selects TransPerfect’s TI GlobalLearn learning management system
Privately owned biotech company Symphogen has chosen TransPerfect Life Sciences’ Trial Interactive (TI) GlobalLearn learning management system to simplify learning in clinical trials.
HCL Technologies, Oracle partner to scale mHealth in clinical trials
Global technology company HCL Technologies and Oracle Health Sciences have partnered to scale up mHealth in clinical trials.
Phesi launches AI-powered clinical trial investigator tool ClinSite
Phesi has launched ClinSite, a self-service, artificial intelligence (AI)-powered tool which enables biopharmaceutical companies to search for top-performing investigator sites for clinical trials in all therapeutic areas.
Opdivo (Nivolumab) for the Treatment of Unresectable or Metastatic Melanoma
Opdivo (nivolumab) is indicated for the treatment of unresectable or metastatic melanoma in patients with a positive BRAF V600 mutation who were previously treated and made progresssion with Yervoy (ipilimumab).
Soliris – Treatment for PNH, aHUS, gMG, and NMOSD
Soliris (eculizumab) is a drug indicated for the treatment of paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uremic syndrome (aHUS), generalised myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).
Cincinnati Children’s new AI system reduces patient screening time
Researchers at Cincinnati Children’s Hospital Medical Center in the US have designed and tested a new computerised solution which uses artificial intelligence (AI) to effectively identify eligible participants from electronic health records (EHRs).
Latest News
Close
Close
Close
Go Top
